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Abstract  13 
Simian foamy viruses (SFVs) are complex retroviruses widespread throughout nonhuman 14 
primates. SFVs can also be transmitted to humans, mostly through bites. We previously observed 15 
that the primary zoonotic gorilla SFV strains much more slowly than laboratory-adapted chimpanzee 16 
strains. Here, we tested the hypothesis that SFV growth is limited by interferon (IFN)-induced 17 
restriction factors using inhibitors of cellular signaling pathways involved in type I IFN induction or 18 
action. Inhibitors of JAK1/2 (Ruxolitinib) and TBK-1 (BMX795) led to a 2 to > 20-fold higher 19 
percentage of infected BHK-1 and HT1080 cells. However, replication of the laboratory-adapted 20 
prototype foamy virus was not sensitive to these molecules, and IKK2 inhibitors had no effect on 21 
any of the SFV strains. In conclusion, the addition of small molecules that inhibit type I IFN response 22 
to the culture medium can be used as a simple and efficient method to enhance the replication of 23 
zoonotic gorilla SFVs. 24 
Keywords  25 
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Introduction 28 
Simian foamy viruses (SFVs) are complex retroviruses widespread throughout nonhuman 29 
primates (NHPs) (reviewed in [1]). SFVs can also be transmitted to humans through bites, 30 
establishing a persistent infection [1-5]. To date, neither pathogenic effects nor secondary 31 
transmission between humans have been reported [5, 6]. Replication-competent SFVs have been 32 
isolated from blood cells years or even decades after infection [7-9] and cell-associated SFV DNA has 33 
been detected in human blood and buccal samples [2, 8, 10-14]. An understanding of the persistence 34 
of SFV in humans and its consequences requires in vitro experiments performed with primary 35 
strains. Indeed, strains may differ in cell tropism and susceptibility to inhibition by innate and 36 
adaptive immune effector molecules and cells [7, 9, 15, 16]. However, repeated cycles of in vitro 37 
production may lead to the selection of the fittest viral variants in specific cell-culture conditions 38 
and/or the expansion of strains that would have been efficiently repressed in vivo by immune 39 
responses. Thus, tropism and susceptibility to IFNs or antibodies frequently differ between 40 
laboratory-adapted and primary strains of retroviruses [17-20]. 41 
Central African villagers from East and South Cameroon and North Gabon are at high risk for 42 
SFV acquisition and approximately 75% of infected individuals carry strains from gorillas [2, 6, 10, 43 
21]. The only gorilla SFV isolated directly from an animal has limited in vitro replication capacity [22]. 44 
We previously isolated two zoonotic gorilla SFV strains and demonstrated their high genetic 45 
similarity with their NHP counterparts [9, 23]. The sequences of these primary viral strains are 46 
identical to those of gene fragments amplified from human PBMC-associated viral DNA [9]. Next, 47 
we performed in vitro infections, using viral stocks produced after inoculation with original or first 48 
passage cell lysates which are referred to as primary strains [15, 16, 24]. We observed that primary 49 
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gorilla SFV grow more slowly than laboratory-adapted chimpanzee SFV on hamster kidney (BHK-21) 50 
cells, which are used for their isolation and production [24]. Furthermore, primary gorilla SFV stocks 51 
collected from cell cultures displaying an extensive cytopathic effect have 100-fold lower cell-free 52 
titers on the GFAB indicator cells in which their autologous LTR directs the expression of a reporter 53 
molecule [24]. 54 
Among host factors that affect replication efficacy, the induction and action of IFN are of 55 
outmost importance [25, 26]. SFVs are sensitive to the action of type I IFNs [15, 27, 28]. Tripartite 56 
motif protein 5α, APOBEC3 cytidine deaminase, N-myc interactor, IFN-induced protein 35, and 57 
tetherin all inhibit SFV replication [3, 29-31]. Systematic screening of IFN-stimulated genes (ISGs) 58 
has identified additional SFV inhibitors [32]. In plasmacytoid dendritic cells, SFVs trigger type I IFN 59 
production after sensing through TLR7 [15]. Cytosolic pattern-recognition receptors recognize viral 60 
nucleic acids and initiate a molecular cascade, resulting in IRF3, IRF7 and/or NF-κB translocation to 61 
the nucleus and the triggering of IFN gene and ISG transcription [25]. Cytoplasmic sensing of SFV 62 
occurs in monocytic cells [33]. However, SFV sensing has not yet been demonstrated in 63 
nonhematopoietic cells [34, 35]. Secreted IFN binds to its cellular receptor and initiates a signaling 64 
cascade through the Janus kinase signal transducer and activator of transcription (JAK-STAT) 65 
pathway [25, 26].    66 
The titers of primary gorilla SFV stocks produced on BHK-21 cells are usually low and 67 
sometimes insufficient to carry out in vitro infections. Therefore, we tested three strategies to 68 
enhance the level and/or speed of primary gorilla SFV replication: the search for sensitive human 69 
cell lines, improvement of viral entry, and blockade of the type I IFN response. The third approach 70 
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was successful, as small molecules that inhibit IFN signaling or the IFN response enhanced the 71 
replication of zoonotic gorilla SFVs. 72 
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Results 74 
Primary gorilla SFV strains replicate more slowly than laboratory-adapted chimpanzee 75 
SFV strains 76 
BHK-21 and HT1080 cells were infected at the same moi with primary zoonotic gorilla SFV 77 
strains GI-D468 and GII-K74 and laboratory-adapted chimpanzee SFV strains CI-PFV and CII-SFV7 [9, 78 
24, 36]. Infection was monitored by flow cytometry. GI-D468 and GII-K74 replicated at the same rate 79 
in both BHK-21 and HT1080 cells and massive cell lysis was observed at day 25 (Figures 1a and 1b). 80 
CI-PFV and CII-SFV-7 spread rapidly in BHK-21 cells reaching 90% of infected cells by day 14, before 81 
the destruction of the cell monolayer (Figure 1a). The growth kinetics of the two chimpanzee strains 82 
were even more rapid in HT-1080 cells, infecting approximately 80% of the cells by day 6 (Figure 1b).  83 
We then tested the infection of several human hematopoietic cell lines. In preliminary 84 
experiments, gorilla SFV appeared to grow at a very slow rate: only 11% of K562 cells infected with 85 
undiluted gorilla SFV expressed Env after 41 days in culture. We therefore tested the susceptibility 86 
of four additional cell lines using the fast replicating CI-PFV. K562 cells were productively infected 87 
using a moi of 0.6, with an infection level of 75% at day 23, before cell lysis (Figure 1c). Raji, Jurkat, 88 
THP-1, and HEL 92.1.7 cells did not express SFV Env during a 41 day-long culture. We used a moi of 89 
0.6 which is 10-fold higher that the maximum reachable with our primary SFV stocks. Unfortunately, 90 
concentration of gorilla SFV particles by iodixanol-gradient ultracentrifugation or centrifugal filters 91 
resulted in reduced infectivity and lower infectious titers on GFAB cells (data not shown). Therefore, 92 
we did not further investigate the susceptibility of various cell lines to gorilla SFV. We monitored the 93 
appearance of CPE in human fibroblasts (MRC5), U-87MG, murine mus dunni, and simian IFN-94 
deficient VERO cells before constructing the GFAB indicator cells and receiving the anti-Env 95 
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monoclonal antibody. All showed similar or even lower susceptibility to gorilla SFV than BHK-21 cells 96 
(Lambert, Gouzil and Buseyne, data not shown). In conclusion, human adherent HT1080 cells were 97 
susceptible to infection with primary gorilla SFV strains which spread more slowly than the 98 
chimpanzee SFV strains. 99 
Procedures targeting the early steps of the replication cycle do not enhance infection 100 
with gorilla SFV 101 
When expressed at the cell surface, SFV Env-mediated fusion is inducible by short exposure 102 
to acidic pH [37] and the fusion process is much slower for macaque SFV Env than CI-PFV Env [38]. 103 
We therefore tested whether changing the pH could enhance infection with viral particles. GFAB 104 
cells were infected for 2 h, exposed to pH 7 or pH 5.5 for 1 or 15 min, and cultured for 72 h. Exposure 105 
to acidic pH did not significantly increase the number of cells infected with any of the four SFV strains 106 
(Figure 2a), whereas it increased cell fusion by PFV Env [37] and gorilla SFV Env (data not shown) 107 
after transfection with plasmids expressing env gene.  108 
Cationic polymers can increase the adsorption of virions on target cell membranes, leading to 109 
the enhancement of infection of some retroviruses [39]. We infected GFAB cells with CI-PFV or GI-110 
D468 in the presence of polyethylenimine, polybrene, or DEAE dextran at concentrations ranging 111 
from 0.5 to 8 µg/mL. Cationic polymers did not increase infection (Figure 2b).  112 
IFN inhibitors enhance infection with gorilla SFVs 113 
We addressed whether SFV replication is sensitive to type I IFN-mediated restriction by adding 114 
small molecules that inhibit either kinases involved in IFN induction (TBK-1and IKK2) or the JAK-STAT 115 
pathway [40-42]. Inhibitors of JAK1/2 (Ruxolitinib), TBK-1 (BX795), or IKK2 (TPCA-1 and BMS345541) 116 
were added for 4 h before GFAB cell infection and during the 72 h-long culture. Ruxolitinib and 117 
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BX795 increased the number of GFAB cells infected with GII-BAK74 by a factor of two (Figure 3a). 118 
Neither molecule increased infection with CI-PFV. No additive effect was observed if both molecules 119 
were mixed. At the highest concentrations tested, we observed a cytotoxic effect that was more 120 
obvious for BX795.  121 
Neither of two IKK2 inhibitors affected GFAB-cell infection with either CI-PFV or GII-K74 122 
(Figure 3b). Thus, blocking IFN signaling through JAK1/2 or the TBK-1-dependent IFN response 123 
increased GFAB-cell infection with GII-K74, whereas it had no effect on infection with CI-PFV. 124 
We further characterized the effect of ruxolitinib on several cycles of SFV replication in GFAB 125 
and HT1080 cells and followed Env expression by flow cytometry. GI-D468 and GII-K74 efficiently 126 
spread in GFAB and HT1080 cells treated with ruxolitinib (Figures 4a and 4b). At day 8 post-infection, 127 
23% of the ruxolitinib-treated GFAB cells were infected with GI-D468 versus 0.6% of the untreated 128 
cells (Figure 4a). In addition, ruxolitinib increased GI-D468 infection of HT1080 cells (16.2% vs. 3.4% 129 
infected cells, Figure 4b). We observed a similar effect for GII-K74, although it was less efficient than 130 
for HT1080 cells (Figure 4a-b). Ruxolitinib did not affect the intensity of envelope protein staining. 131 
It also had no effect on infection of HT1080 cells with CI-PFV (Figure 4c), in accordance with the 132 
results on GFAB cells (Figure 3a). These data show that treatment with ruxolitinib significantly 133 
enhanced the number of cells infected with primary gorilla SFVs but not those infected with CI-PFV.  134 
  135 
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Discussion 136 
Here, we sought to increase the in vitro replication of primary gorilla SFV strains and found 137 
that inhibition of the type I IFN response is an efficient way to achieve such a goal. Indeed, the 138 
supplementation of culture medium with JAK1/2 or TBK-1 inhibitors is a simple and broadly 139 
applicable method, efficient for a variety of viruses [41-43], including retroviruses [44]. While the 140 
growth of primary gorilla SFV was sensitive to inhibition of the IFN response, the growth of 141 
laboratory-adapted CI-PFV was not. 142 
The blockade of IFN signaling by JAK1/2 inhibitors and the TBK-1-mediated IFN response 143 
increased gorilla SFV replication. In contrast, blocking IKK2, which is another component of the IFN 144 
response, had no effect on in vitro SFV growth. Our data indirectly suggest that gorilla SFV activates 145 
the IRF3 but not the classical NF-κB pathway. Indeed, CI-PFV induces IRF3-dependent ISGs in human 146 
monocytes [33]. However, its replication was not enhanced by TBK-1 inhibition in our hands. This 147 
discrepancy may be explained by differences in innate sensing between hematopoietic and 148 
nonhematopoietic cells, as CI-PFV is unable to induce IFN production in nonhematopoietic cells [34, 149 
35]. Alternatively, the rapid and high level of PFV replication may saturate antiviral molecules 150 
targeted by the drugs we used.  151 
We tested the susceptibility of several human cell lines to primary gorilla SFVs. No gorilla cell 152 
lines or samples are available to test the replication kinetics of gorilla SFV in their natural host cells. 153 
Here, we focused on human cells because SFV infection in humans is our major research theme and 154 
because more cell biology and immunology reagents are available for their study. We observed that 155 
CI-PFV replicates faster in HT1080 than in BHK-21 cells, as reported by others [45]. HT1080 cells 156 
were susceptible to both GI-D468 and GII-K74, but both gorilla SFVs had similar replication kinetics 157 
 10 of 28 
 
in HT1080 and BHK-21 cells. Overall, we observed the slow/low replication kinetics of gorilla SFV in 158 
both the hamster cells used for their isolation and human fibroblasts, described to have the highest 159 
susceptibility to CI-PFV [45]. 160 
CI-PFV infects a wide range of adherent and nonadherent cells [46-48]. Here, we tested the 161 
infection of five myeloid and lymphoid human cell lines with the fast-growing CI-PFV. We used a low 162 
moi for our study, i.e. a screen of cells that could be infected at an moi achievable with primary 163 
gorilla SFV stocks. Under these conditions, only K562 cells were susceptible to PFV infection. The 164 
low moi is a likely explanation for the low cell susceptibility to CI-PFV in this study relative to that 165 
reported in previous publications [47, 49, 50].  166 
We tested several classical methods to enhance the early steps of SFV infection. The use of 167 
polycations to reduce surface charge had no impact on gorilla SFV, as reported by others for PFV 168 
[48, 51]. The process regulating SFV Env fusogenic activity and variation across various viral species 169 
is not fully defined [37]. Although exposure to a pulse of acidic pH induced fusion of gorilla SFV Env 170 
expressed at the cell surface, as described in [37] we observed no effect on SFV Env exposed at the 171 
surface of viral particles. We hypothesized that gorilla SFV Env fusion is a slow process, as described 172 
for macaque SFV Env [38], and exposed cells to low pH after incubation with the viral inoculum. This 173 
timing might be suboptimal if most of the particles were already internalized and unaffected by the 174 
change in the pH of the culture medium. Of note, we recently produced chimeric foamy virus vectors 175 
expressing gorilla SFV Env and CI-PFV Gag and Pol, for which the titers were equal to or marginally 176 
lower (< 5-fold) than those of vectors expressing CI-PFV Env [16]. Overall, our data argue against a 177 
restriction of gorilla SFV replication at the Env-mediated early steps of the viral cycle. 178 
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We aimed to avoid the selection of fast-growing laboratory-adapted gorilla SFV strains for the 179 
realization of in vitro infections. We show here that the presence of ruxolitinib during the production 180 
of gorilla SFV stocks is a simple way to overcome the slow/low in vitro replication of these strains. 181 
At first glance, blocking restriction mechanisms to enhance SFV growth does not appear to fit our 182 
initial goal, because viral particles produced in ruxolitinib-treated cells may differ from those 183 
produced in untreated cells, with active innate sensing and an IFN response. It will thus be critical 184 
to consider the final experimental outcome before producing viral stocks with IFN blockade. In 185 
addition, we propose the use of ruxolitinib for a single round of virus amplification, starting from 186 
original material for each new round of production to limit the selection of fitter viral variants over 187 
serial passages.   188 
Although we focused on the production of primary SFV stocks, our results may be relevant for 189 
the isolation of new replicating SFV strains. Our current procedure relies on the stimulation of 190 
human peripheral blood cells to induce viral replication and coculture with susceptible cells from a 191 
nonhuman species to avoid inhibition by human IFN-γ and other soluble mediators produced by 192 
activated PBMCs [9, 10, 52]. The use of small-molecule inhibitors of the type I IFN response may be 193 
useful for improving the isolation of new primary SFV, as demonstrated by the inhibition of IFN-γ 194 
[52].  195 
In conclusion, we show that the addition of JAK1/2 or TBK-1 inhibitors to culture medium is a 196 
simple and efficient procedure to enhance the growth of slow/low primary gorilla SFV isolates. The 197 
same inhibitors did not enhance replication of the laboratory-adapted CI-PFV, showing the utility of 198 
primary SFV strains for the study of innate sensing. Our results should be useful for researchers in 199 
the field of foamy viruses. 200 
 12 of 28 
 
Materials and Methods  201 
Cells 202 
K562 (ECACC 89121407, human erythroleukemia cells) and BHK-21 (ATCC-CLL-10, hamster 203 
kidney fibroblasts) cells were obtained from colleagues at the Institut Pasteur. BHK-21-derived 204 
gorilla foamy virus-activated β-galactosidase (GFAB) cells were generated in our laboratory [24]. 205 
Other cell lines were purchased from LGC standards or Sigma-Aldrich and stocks were produced 206 
after less than 10 passages. The cells were screened for mycoplasma infection every 10 passages 207 
with a bioluminescent assay (#LT07-418, Lonza). The HT1080 cells (ECACC 85111505, human 208 
fibrosarcoma) were cultivated in Eagle’s Minimum Essential Medium with Earle's Balanced Salts and 209 
L-Glutamine (EMEM-EBSS, Lonza) supplemented with 10% fetal bovine serum (FBS, PAA 210 
Laboratories) and 1% nonessential amino acids (NEAA, Invitrogen). K562, HEL 92.1.7 (ATCC-TIB-180, 211 
human erythroleukemia cells), THP-1 (ECACC 88081201, human monocytic leukemia cells), Raji 212 
(ATCC-CCL-86, human B lymphoma cells), and Jurkat (ATCC-TIB-152, human T leukemia cells) were 213 
grown in RPMI medium containing GlutaMAX I (Invitrogen) supplemented with 10% FBS. BHK-21 214 
and GFAB cells were cultivated in Dulbeco’s modified Eagle’s medium (DMEM-GlutaMAX I, 215 
Invitrogen) supplemented with 5% FBS. G418 (300 µg/ml, Sigma-Aldrich) was added to the GFAB 216 
cultures.  217 
Viruses 218 
SFV strains consisted of the primary zoonotic gorilla SFVs, SFVggo_huBAD468 (GI-D468) and 219 
SFVggo_huBAK74 (GII-K74) [9], and the laboratory-adapted chimpanzee SFVs, SFVpsc_huPFV (CI-220 
PFV) and SFVpve_Pan2 (CII-SFV7) [33]. GI-D468 and GII-K74 viral stocks were produced by infecting 221 
BHK-21 cells with original or first passage cell lysates. CI-PFV and CII-SFV7 viral stocks were obtained 222 
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by a single round of infection with aliquots obtained from A. Saib and A. Rethwilm, respectively. 223 
Infected cultures were passaged twice a week and uninfected cells added after the appearance of 224 
the first syncytia to amplify the virus. Once the cytopathic effect (CPE) had destroyed > 70% of the 225 
cell layer, infected cells and supernatants were treated by three cycles of freezing and thawing (-226 
80°C; +37°C) to enable the release of viral particles. The lysate was cleared by centrifugation (1500 227 
x g for 10 min), filtered through a 0.45 µm pore-size filter, and stored as single-use aliquots at -80°C. 228 
Both chimpanzee and gorilla SFV are efficiently detected by GFAB cells [24]. Virus titers were 229 
determined by infecting GFAB cells at 30 to 40% confluence in flat-bottom 96-well plates with 30 230 
µl/well of serially-diluted viral solutions prepared in DMEM. After a 2-h incubation, 170 µl DMEM-231 
5% FBS was added to each well. Tests were performed in triplicate. The cells were fixed after 72 h 232 
with 0.5% glutaraldehyde in a phosphate-buffered saline solution (PBS) for 10 min at room 233 
temperature (RT). Cells were washed with PBS and incubated 1 h at 37°C with an X-Gal staining 234 
solution (2 mM MgCl2; 10 mM Potassium ferricyanide, 10 mM Potassium ferrocyanide; and 0.5 235 
mg/mL 5-Bromo-4-chloro-3-indolyl-B-D-galactopyranoside in PBS). An Ultimate UV Image analyzer 236 
(CTL Europe, Bonn, Germany) was used to count X-Gal stained cells. One infectious unit was defined 237 
as a blue cell or syncytia. 238 
SFV infections 239 
Adherent cells were infected at 30 to 40% confluence. On the day before the infection, BHK-240 
21 and GFAB cells were seeded at 5 103 cells/P96-well and HT1080 were seeded at 2.5 103 cells/P96 241 
well. Adherent cells were infected at 30 to 40% confluence with 25µl of undiluted GI-D468 and GII-242 
K74 (5 103 infectious unit (IU)/ml). CI-PFV (2 106 IU/ml) and CII-SFV7 (3 105 IU/ml) stocks were 243 
diluted to achieve the same moi as the gorilla SFV strains in experiments comparing the four strains. 244 
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The corresponding moi were 0.01 for BHK-21 and GFAB cells, 0.02 for HT1080. Certain CI-PFV 245 
infections were carried out at a 10-fold higher moi to reduce the length of the experiments. Non-246 
adherent cells (106 cells) were centrifuged at 500 x g before the addition of the 500 µl of CI-PFV to 247 
the cell pellet. Infected cultures were passaged twice a week by dilution into fresh culture medium 248 
at the same cell density as for the propagation of uninfected cells and maintained up to the 249 
occurrence of a massive CPE. GFAB cells were infected in triplicate using the titration protocol and 250 
stained after 72 h. The corresponding means and standard deviations (SD) were calculated. 251 
Exposure to acidic pH was performed 2 h post-infection by removing the medium, adding PBS 252 
at pH 7 or 5.5, and incubation for 1 or 15 min. The PBS was discarded and DMEM with 5% FBS added 253 
to the wells. Polyethyleneimine (jetPEI, #101-10, Polyplus), 1,5-dimethyl-1,5-diazaundecamethylene 254 
polymethobromide (Polybrene, # TR-1003, Sigma-Aldrich), and diethylaminoethyl dextran (DEAE 255 
Dextran, wt 500.000, #D9885 Sigma-Aldrich) were added to the viral inoculum immediately before 256 
the infection of GFAB cells. Inhibitors of JAK1/2 (Ruxolitinib, #S1378, Euromedex), TBK-1 (BX795, 257 
#S1274, Euromedex), and IKK2 (TPCA-1, #T1452 and BMS345541, #B9935, Sigma-Aldrich) were 258 
added to the culture medium after a 2-h incubation with the viral inoculum. 259 
Flow cytometry 260 
A murine monoclonal antibody specific for the leader peptide of the SFV envelope (clone 261 
P6G11G11 generated by M.L. Linial) was conjugated to Alexa Fluor 647 dye (anti-Env-AF647). 262 
Antibody production, coupling, and purification were performed by RD Biotech, Besançon, France. 263 
Cells were fixed with 2% paraformaldehyde (PFA) diluted in PBS for 10 min at RT, washed in PBS 264 
supplemented with 0.1% bovine serum albumin (BSA), permeabilized with 0.5% Triton X-100 in PBS-265 
0.1% BSA for 10 min at RT, washed before addition of anti-Env-AF647 at 20 ng/mL and viability dye 266 
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(0.5 µl/tube, Live Dead Aqua, #L34957, Life Technologies), and incubated for 30 min at RT. Cells were 267 
washed with PBS-0.1%BSA and resuspended in 300 µL PBS-2%PFA. Data was acquired on a Gallios 268 
cytometer (Beckman Coulter) and analyzed with Kaluza software. Results are expressed as the 269 
percentage among viable cells. 270 
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Figure legends 396 
Figure 1. Replication kinetics of SFVs in several cell lines. (a) BHK-21 and (b) HT1080 cells 397 
were infected with CI-PFV (black), CII-SFV7 (green), GI-D468 (blue), or GII-K74 (red) at a moi of 0.01 398 
for BHK-21 cells and 0.02 for HT1080. (c) K562, Jurkat, Raji, THP-1, and HEL 92.1.7 cells were infected 399 
with CI-PFV at a moi of 0.6. Infected cultures were split twice a week and a fraction of the cells 400 
stained with a viability marker and an anti-Env-AF647 antibody. Cultures were maintained until their 401 
death due to a massive cytopathogenic effect. The percentage of Env+ cells among live cells is 402 
presented as a function of time. The lack of symbols at day 25 in panels a and b indicate that most 403 
cells expressed Env but that their accurate quantification was not possible because most were 404 
already dead. The data correspond to a representative test of two (panel c) or three independent 405 
experiments (panel a and b).  406 
Figure 2. Factors affecting early steps of the replication cycle have no effect on infection 407 
with SFV. (a) Effect of reducing pH treatment on SFV replication. GFAB cells were infected with CI-408 
PFV, CII-SFV7, GI-D468, or GII-K74 at a moi of 0.01. Two hours post-infection, medium was removed 409 
and PBS at pH 7 or 5.5 added and the cultures incubated for 1 or 15 min. After 72 h of infection, β-410 
galactosidase expression was detected by X-gal staining. The number of infected cells/well is shown 411 
as the mean and SD of triplicates. (b) Effect of cationic polymers on SFV replication. GFAB cells were 412 
infected with CI-PFV (black) or GI-D468 (blue) viruses at a moi of 0.01 in the presence of 413 
polyethyleneimine (PEI), polybrene (PB), or DEAE Dextran (DEXT) at various concentrations. After 72 414 
h of infection, β-galactosidase expression was detected by X-gal staining. The number of infected 415 
cells/well is shown as the mean and SD of triplicates. All the data correspond to a representative 416 
experiment of three independent experiments. 417 
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Figure 3. Effect of inhibitors of the IFN response on SFV replication. GFAB cells were treated 418 
with IFN inhibitors for 4 h at various concentrations prior to infection. After 72 h of infection, β-419 
galactosidase expression was detected by X-gal staining. The number of infected cells/well is shown 420 
as the mean and SD of triplicates. (a) GFAB cells were treated with ruxolitinib, BX795, or a mix of the 421 
two molecules and infected with CI-PFV (black, moi 0.1) or GII-K74 (red, moi 0.02). (b) GFAB cells 422 
were treated with TPCA-1 or BMS345541 and infected with CI-PFV (black, moi 0.1) or GII-K74 (red, 423 
moi 0.02). All the data correspond to a representative experiment of three independent 424 
experiments.   425 
Figure 4. Ruxolitinib enhances replication of gorilla SFV but has no effect on CI-PFV. GFAB 426 
(a) and HT1080 (b and c) cells were treated with ruxolitinib at 10 µM for 4 h and infected with SFV 427 
strains at a moi of 0.02. Infected cultures were stained twice a week with a viability marker and an 428 
anti-Env-AF647 antibody. Data are presented at the peak of infection on a FSC/anti-Env dot-plot of 429 
viable cells. Percentages of Env+ cells are indicated. (a) GI-D468, day 8 post-infection; (b) GII-K74, 430 
day 8 post-infection; (c) CI-PFV, day 5 post-infection.   431 
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